Merck’s skin-drug win keeps rolling

Another green light for Merck’s pipeline

Merck just checked another box for tulisokibart, saying the drug met its primary and key secondary endpoints in a Phase 2b study in patients with moderate to severe hidradenitis suppurativa. That’s the kind of update investors like to see: not a splashy approval, but a meaningful step that says the science is still doing its job.

Why this matters

Hidradenitis suppurativa is a nasty, chronic inflammatory skin disease, and that makes it a juicy target if you’re trying to build a blockbuster. If tulisokibart can keep stringing together solid data, Merck gets more optionality in a pipeline that’s increasingly doing the heavy lifting behind Keytruda.

The investor angle

A Phase 2b win doesn’t print money on its own, but it can change the odds board. Here’s what investors are watching:

• whether the data hold up in later-stage studies
• how tulisokibart compares with existing therapies
• whether Merck can turn this into a broader inflammation franchise

Big picture: Merck doesn’t need every pipeline asset to be a hero, but it sure helps when one keeps showing up to work.